Double attack on prostate cancer spread: targeted radiation plus Bone-Seeking drug tested
NCT ID NCT04037358
Summary
This study tested whether adding a bone-targeting radioactive drug (Radium-223) to precise, high-dose radiation (SABR) works better than radiation alone for men whose prostate cancer has spread to a few spots, including at least one in bone. The goal was to see if this combined approach could keep the cancer from growing or spreading longer. Researchers compared the two treatments in 64 men to measure how long they remained progression-free.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Johns Hopkins
Baltimore, Maryland, 21287, United States
Conditions
Explore the condition pages connected to this study.